Mikhail Eydelman Sells 1,667 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) SVP Mikhail Eydelman sold 1,667 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $76.37, for a total value of $127,308.79. Following the completion of the sale, the senior vice president now directly owns 30,826 shares in the company, valued at approximately $2,354,181.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Mikhail Eydelman also recently made the following trade(s):

• On Monday, June 3rd, Mikhail Eydelman sold 1,667 shares of Vaxcyte stock. The shares were sold at an average price of $72.06, for a total value of $120,124.02.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $76.26 on Thursday. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $82.04. The business’s 50 day moving average is $70.52 and its 200-day moving average is $68.28.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.28. As a group, analysts anticipate that Vaxcyte, Inc. will post -3.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PCVX. Needham & Company LLC reaffirmed a “buy” rating and issued a $95.00 target price on shares of Vaxcyte in a report on Friday, June 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th.

Institutional Trading of Vaxcyte

Several institutional investors have recently modified their holdings of the company. Xponance Inc. lifted its position in shares of Vaxcyte by 3.0% during the 4th quarter. Xponance Inc. now owns 5,672 shares of the company’s stock worth $356,000 after buying an additional 163 shares during the period. Ellsworth Advisors LLC lifted its position in shares of Vaxcyte by 2.6% during the 4th quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock worth $506,000 after buying an additional 207 shares during the period. Parallel Advisors LLC lifted its position in shares of Vaxcyte by 155.3% during the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after buying an additional 250 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Vaxcyte by 0.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock worth $3,211,000 after buying an additional 296 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Vaxcyte by 1.7% during the 4th quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock worth $1,382,000 after buying an additional 376 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.